Key result
Liquiritin improves NAFLD lipid metabolism in vitro by regulating the AKT/FOXO1 pathway and macrophage mitophagy.
Why the study?
Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic liver condition with a complex and multifactorial pathogenesis, prompting investigation into the mechanism of liquiritin for its treatment.
Does liquiritin improve lipid metabolism disorders in NAFLD models?
Does liquiritin improve lipid metabolism disorders in NAFLD models?
Liquiritin shows potential as a therapeutic agent for NAFLD by restoring metabolic homeostasis via the AKT1/FOXO1 signaling pathway in preclinical models.
Answers are grounded in this paper and cite their sources.
May support liquiritin for NAFLD mechanisms; hypothesis-generating and requires clinical validation before practice change.
Background Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic liver condition with a complex and multifactorial pathogenesis. Purpose This study aimed to investigate the mecha-nism of liquiritin (LQ) in NAFLD for its treatment. Methods This study integrates bioinformatics analysis with in vitro validation. Bulk RNA-seq analysis and single-cell dataset analysis were performed using Gene Expression Omnibus database resources. Molecular docking and molecular dynamics simulations were employed to evaluate the binding affinity of liquiritin with lipid metabolism-related proteins AKT and FOXO1. In vitro validation was conducted using the HepG2, AML12 and RAW 264.7 to investigate the mechanism by which liquiritin regulates lipid metabolic homeostasis in HepG2 cells and AML12 cells via the AKT/FOXO1 pathway through protein immunoblotting and immunofluorescence. The effects of liquiritin on mitochondrial autophagy in RAW 264.7 cells were also examined. Results Bulk RNA-seq analysis identified FOXO1 as a key target, while single-cell analysis predicted interactions between hepatocytes and macrophages in non-alcoholic fatty liver disease (NAFLD). Molecular docking predicted a potential stable interaction between liquiritin and FOXO1. In HepG2 cells and AML12 cells, liquiritin improved NAFLD lipid metabolism disorders by regulating the AKT/FOXO1 pathway. Liquiritin also modulates the expression of mitophagy-associated proteins in RAW264.7 cells. Conclusion Liquiritin improves lipid metabolism disorders in NAFLD by regulating the AKT/FOXO1 pathway, while also potentially influencing macrophage function. This suggests its potential as a candidate therapeutic agent for non-alcoholic fatty liver disease.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied Non-alcoholic fatty liver disease (NAFLD). Liquiritin vs. Free fatty acid (FFA) model was evaluated on Lipid accumulation and AKT/FOXO1 pathway modulation. Liquiritin improved NAFLD lipid metabolism disorders in vitro by regulating the AKT/FOXO1 pathway and modulating mitophagy-associated proteins in macrophages.
Synapse has enriched 10 related papers. Consider them for comparative context: